Samsara Bio Capital, LLC Avadel Pharmaceuticals PLC Transaction History

Samsara Bio Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$8.48 - $16.48 $3.75 Million - $7.28 Million	-441,882 Reduced 31.35%	967,527 $15.9 Million
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $9.03 Million - $14 Million	1,409,409 New	1,409,409 $12.9 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $808,567 - $1.23 Million	110,159 Added 20.06%	659,409 $5.33 Million
Q1 2021 May 18, 2021	BUY	$6.61 - $10.07 $760,150 - $1.16 Million	115,000 Added 26.48%	549,250 $4.97 Million
Q4 2020 Feb 17, 2021	BUY	$5.03 - $7.95 $2.18 Million - $3.45 Million	434,250 New	434,250 $2.9 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.